Delivery Order SPE2DB24D1205-SPE2DB25FCYYR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units) with a ceiling value of $9,241.86. This firm fixed-price delivery order, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award supporting federal medical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The U.S. Defense Logistics Agency Troop Support Medical has awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a $4,466.57 firm fixed price delivery order contract to supply Zeposia 0.92 mg capsules. This order is issued under an indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical. The IDC serves as the primary vehicle for Amerisourcebergen to provide pharmaceuticals and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count units) under a firm fixed-price contract valued at $4,620.93, with an ultimate completion date of August 13, 2025. This non-set-aside competitive award reflects AmerisourceBergen's capability to deliver pharmaceutical products to support federal medical procurement needs. The contract is executed out of the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $13,862.79 to AmerisourceBergen Drug Corp for Zeposia 0.92 mg capsules (30-count) on July 24, 2025, with an ultimate completion date of August 14, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs. This delivery order...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency (DLA) for ZEPOSIA 0.92 mg capsules (30-count units) valued at $13,862.79. The award was made on July 28, 2025, under a Firm Fixed Price contract type with an ultimate completion date of August 18, 2025. This non-competitive, non-set-aside delivery order represents a continuation of the company's extensive pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply Zeposia 0.92 mg capsules. The $4,466.57 order has an ultimate completion date of April 3, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through December 31, 2025. This IDC serves as the primary vehicle for...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 MG capsules. The order, valued at $13,399.71, has a firm fixed price and a completion date of September 11, 2024. AmerisourceBergen, a major pharmaceutical distributor, is delivering this medication to support various government healthcare programs and facilities, including military treatment facilities and veterans' hospitals. The contract is not set aside for any...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $13,399.71 Firm Fixed Price Delivery Order is for the supply of Zeposia 0.92 mg capsules, with a completion date of June 4, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999.00 through December 2025. This single-award IDC serves as the primary vehicle for the...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp's Corporate Office Division for the supply of the pharmaceutical product Zeposia 0.92 MG Capsule 30S. The contract is a firm fixed-price delivery order with a ceiling value of $13,399.71 and a completion date of July 22, 2024. AmerisourceBergen, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, holds a single-award Indefinite Delivery Contract (IDC)...
- This is a federal contract award by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,862.79, is for the delivery of Zeposia 0.92 mg capsules. It is a firm fixed-price Delivery Order contract with an ultimate completion date of April 8, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCYYRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for Zeposia 0.92 mg capsules (30-count units) under a firm fixed-price contract valued at $13,862.79. This non-set-aside competitive award, with an ultimate completion date of August 18, 2025, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through December 2026 that enables the pharmaceutical distributor to supply a comprehensive range of medications and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal medical procurement vendor for military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver diverse pharmaceutical products, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. As DLA continues planning for the next generation Pharmaceutical Prime Vendor Global Program Generation V contracts with anticipated multiple regional awards, AmerisourceBergen's performance under existing delivery orders such as this one reinforces its position as a key supplier within the Defense Health Agency's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.9k | 7/28/25 |